Skip to main content
Signal8
Launch Terminal

PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

NASDAQ:PMVPHealthcare
-2.96%$1.31
AH$1.31+0.00%vs close
Mkt Cap$98.92M
Float66.47M
O/S75.51M
Vol
$ Vol
RVOL
Inst Own45.4%
SI3.4%
Earnings
Dilution
PMV Pharmaceuticals, Inc. logoNASDAQ:PMVP$1.31-2.96%
Phase Distribution
6 lead-sponsored trials·2 active·4 completed
Phase 15
Phase 1/21
(1 more as collaborator)
Status Overview
Recruiting2
Completed4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 1/2
    Recruiting

    The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    rezatapopt, pembrolizumab

    Advanced Solid Tumor, Advanced Malignant Neoplasm +28

    Enrollment
    300
    Start
    Oct 2020
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2027est.
    NCT04585750
  • Phase 1
    Completed

    Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers

    PC14586

    Healthy Volunteers

    Enrollment
    34
    Start
    Dec 2021
    Primary Completion
    Jun 2022
    Completion
    Jun 2022
    NCT05249348
  • Phase 1
    Completed

    AME Study of [14C]-PC14586 in Healthy Male Participants

    [14C]-PC14586

    Healthy Male Volunteers

    Enrollment
    8
    Start
    Sep 2022
    Primary Completion
    Nov 2022
    Completion
    Nov 2022
    NCT05523687
  • Phase 1
    Completed

    A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

    PC14586, Rabeprazole

    Healthy Volunteers

    Enrollment
    28
    Start
    Sep 2023
    Primary Completion
    Nov 2023
    Completion
    Feb 2024
    NCT06054464
  • Phase 1
    Completed

    A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants

    PC14586, Itraconazole

    Healthy Volunteers

    Enrollment
    12
    Start
    Mar 2024
    Primary Completion
    Oct 2024
    Completion
    Oct 2024
    NCT06362642
  • Phase 1
    Recruiting

    A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

    metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet

    TP53 Y220C Mutation, Advanced Solid Tumors

    Enrollment
    14
    Start
    Feb 2026
    Primary Completion
    Mar 2027est.
    Completion
    Jan 2028est.
    NCT07372625
Search ClinicalTrials.gov for “PMV Pharmaceuticals”